HKD 9.64
(4.1%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 963.05 Million CNY | 22.65% |
2022 | 785.88 Million CNY | 7.85% |
2021 | 728.71 Million CNY | 17.76% |
2020 | 618.78 Million CNY | 9.26% |
2019 | 566.35 Million CNY | -21.74% |
2018 | 723.7 Million CNY | 21.13% |
2017 | 597.46 Million CNY | 36.56% |
2016 | 437.52 Million CNY | 40.0% |
2015 | 312.51 Million CNY | 24.66% |
2014 | 250.69 Million CNY | 14.92% |
2013 | 218.14 Million CNY | 13.18% |
2012 | 192.74 Million CNY | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | 453.5 Million CNY | 0.0% |
2023 FY | - CNY | 22.65% |
2023 Q4 | 501.95 Million CNY | 0.0% |
2023 Q2 | 395.55 Million CNY | 0.0% |
2022 Q2 | 333.96 Million CNY | 0.0% |
2022 FY | - CNY | 7.85% |
2022 Q4 | 451.92 Million CNY | 0.0% |
2021 Q2 | 321.43 Million CNY | 0.0% |
2021 FY | - CNY | 17.76% |
2021 Q4 | 407.27 Million CNY | 0.0% |
2020 Q4 | 337.49 Million CNY | 0.0% |
2020 FY | - CNY | 9.26% |
2020 Q2 | 281.29 Million CNY | 0.0% |
2019 Q4 | 207.52 Million CNY | 0.0% |
2019 FY | - CNY | -21.74% |
2019 Q2 | 358.83 Million CNY | 0.0% |
2018 Q4 | 384.1 Million CNY | 0.0% |
2018 Q2 | 339.6 Million CNY | 0.0% |
2018 FY | - CNY | 21.13% |
2017 Q2 | 295.85 Million CNY | 0.0% |
2017 FY | - CNY | 36.56% |
2017 Q4 | 301.6 Million CNY | 0.0% |
2016 Q4 | 255.72 Million CNY | 0.0% |
2016 FY | - CNY | 40.0% |
2016 Q2 | 181.8 Million CNY | 0.0% |
2015 Q2 | 146.64 Million CNY | 0.0% |
2015 FY | - CNY | 24.66% |
2015 Q4 | 165.87 Million CNY | 0.0% |
2014 Q2 | 103.19 Million CNY | 0.0% |
2014 Q4 | 147.49 Million CNY | 0.0% |
2014 FY | - CNY | 14.92% |
2013 Q4 | 132.03 Million CNY | 0.0% |
2013 FY | - CNY | 13.18% |
2013 Q2 | 86.11 Million CNY | 0.0% |
2012 Q3 | 47.69 Million CNY | 0.0% |
2012 Q4 | 55.83 Million CNY | 17.06% |
2012 Q2 | 47.69 Million CNY | 0.0% |
2012 Q1 | 47.69 Million CNY | 0.0% |
2012 FY | - CNY | 0.0% |
2011 Q4 | 47.69 Million CNY | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Pak Fah Yeow International Limited | 150.4 Million HKD | -540.33% |
Grand Pharmaceutical Group Limited | 2.96 Billion HKD | 67.536% |
Extrawell Pharmaceutical Holdings Limited | -129.51 Million HKD | 843.558% |
Wai Yuen Tong Medicine Holdings Limited | 113.79 Million HKD | -746.286% |
Qianhai Health Holdings Limited | -50.22 Million HKD | 2017.331% |
Lee's Pharmaceutical Holdings Limited | 109.82 Million HKD | -776.94% |
Essex Bio-Technology Limited | 418.37 Million HKD | -130.189% |
Tongfang Kontafarma Holdings Limited | 76.63 Million HKD | -1156.712% |
PuraPharm Corporation Limited | -26.16 Million HKD | 3780.141% |
SSY Group Limited | 2.11 Billion HKD | 54.456% |
JBM (Healthcare) Limited | 204.39 Million HKD | -371.185% |
Jacobson Pharma Corporation Limited | 429.92 Million HKD | -124.008% |
China Resources Pharmaceutical Group Limited | 15.43 Billion HKD | 93.759% |